Three-Year Visual Outcome and Injection Frequency of Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

Publisher： Karger

E-ISSN： 1423-0267|230|1|27-33

ISSN： 0030-3755

Source： Ophthalmologica, Vol.230, Iss.1, 2013-04, pp. : 27-33

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration

By  

Case Reports in Ophthalmology, Vol. 7, Iss. 1, 2016-04 ,pp. : 230-236

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration with Good Baseline Visual Acuity

By  

Ophthalmologica, Vol. 233, Iss. 1, 2014-11 ,pp. : 27-34

Karger

Access to resources Recommend Favorite

Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial

By  

Ophthalmologica, Vol. 234, Iss. 1, 2015-06 ,pp. : 40-54

Karger

Access to resources Recommend Favorite

A Pilot Study on the Combination Treatment of Reduced-Fluence Photodynamic Therapy, Intravitreal Ranibizumab, Intravitreal Dexamethasone and Oral Minocycline for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 225, Iss. 4, 2011-02 ,pp. : 200-206

Karger

Access to resources Recommend Favorite

Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 231, Iss. 2, 2013-12 ,pp. : 80-85

Karger

Access to resources Recommend Favorite